Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers
Background and objective This review aims to provide an overview of novel diagnostic and
therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers …
therapeutic radiopharmaceuticals tested recently or used currently in genitourinary cancers …
Lu-177-Labeled Hetero-Bivalent Agents Targeting PSMA and Bone Metastases for Radionuclide Therapy
Z Zha, K Ploessl, SR Choi, R Zhao, W Jin… - Journal of Medicinal …, 2023 - ACS Publications
Prostate-specific membrane antigen (PSMA) is an excellent target for imaging and
radionuclide therapy of prostate cancer. Recently,[177Lu] Lu-PSMA-617 (Pluvicto) was …
radionuclide therapy of prostate cancer. Recently,[177Lu] Lu-PSMA-617 (Pluvicto) was …
Head-to-Head Comparison of [18F]PSMA-1007 and [18F]FDG PET/CT in Patients with Triple-Negative Breast Cancer
N Andryszak, D Świniuch, E Wójcik, R Ramlau… - Cancers, 2024 - mdpi.com
Simple Summary This study investigates a promising avenue for improving the diagnosis
and treatment of triple-negative breast cancer (TNBC), a highly aggressive form of breast …
and treatment of triple-negative breast cancer (TNBC), a highly aggressive form of breast …
Estimation of the relative biological effectiveness (RBE) of the Lu− DOTA− iPSMA177<!−− Q1 …
JE de la Fuente-Mendoza, EP Azorín-Vega… - Applied Radiation and …, 2023 - Elsevier
Relative biological effectiveness is a radiobiological parameter relevant in radiotherapy
planning and useful in evaluating the physiological impact of radiation in different tissues …
planning and useful in evaluating the physiological impact of radiation in different tissues …
[HTML][HTML] Medicaid Expansion and Survival Outcomes Among Men With Prostate Cancer
OA Akinyemi, ME Fasokun, E Hercules… - Cureus, 2025 - pmc.ncbi.nlm.nih.gov
Introduction: Prostate cancer stands as one of the most diagnosed malignancies among
men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA) …
men worldwide. With the recent expansion of Medicaid under the Affordable Care Act (ACA) …
Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer
The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues
to be challenging, given the multitude of life prolonging treatment options. Radionuclide …
to be challenging, given the multitude of life prolonging treatment options. Radionuclide …